Re: Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings in Multiparametric MRI (PRIMARY2): A Multicentre, Non-inferiority, Phase 3, Randomised Controlled Trial

doi:10.1016/j.eururo.2026.07.012

Re: Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings in Multiparametric MRI (PRIMARY2): A Multicentre, Non-inferiority, Phase 3, Randomised Controlled Trial

Journal: European urology (Q1)
Published: 16 July 2026
Study design: Randomized controlled trial
Evidence level: Level 1, High (CEBM 1b)
Authors: Luca Urso, Gianluca Giannarini, Rossano Girometti, Alessandro Crestani, Matteo Bauckneht
PMID: 42463362
DOI: 10.1016/j.eururo.2026.07.012

Why clinicians should know about it

Picked for Oncology and Radiation Oncology (top studies of the week, 19 July 2026): RCT of 68Ga‑PSMA PET‑CT in prostate cancer diagnosis
Picked for Radiology, Radiation Oncology, Nuclear Medicine, Medical Physics and Imaging (top studies of the week, 19 July 2026): Phase III RCT, practice-changing for PSMA PET imaging

View on PubMed Full text at the publisher Open in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.